Literature DB >> 11238618

Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).

J W Park1, M E Gruys, K McCormick, J K Lee, J Subleski, J M Wigginton, R G Fenton, J M Wang, R H Wiltrout.   

Abstract

The IFN-gamma-inducible proteins monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2) can contribute to IL-12-induced antiangiogenic and leukocyte-recruiting activities, but the extent to which leukocytes vs parenchymal cells in different organs contribute to the production of these molecules remains unclear. The results presented herein show that IFN-gamma-dependent induction of Mig and Crg-2 gene expression can occur in many nonlymphoid organs, and these genes are rapidly induced in purified hepatocytes isolated from mice treated with IL-2 plus IL-12, or from Hepa 1-6 hepatoma cells treated in vitro with IFN-gamma. In addition to depending on IFN-gamma, the ability of IL-12 or IL-2/IL-12 to induce Mig and Crg-2 gene expression in purified hepatocytes also is accompanied by the coordinate up-regulation of the IFN-gamma R alpha and beta-chains, in the absence of IL-12R components. Supernatants of primary hepatocytes obtained from mice treated in vivo with IL-2/IL-12 or from hepatocytes treated in vitro with IFN-gamma contain increased chemotactic activity for enriched human and mouse CD3(+) T cells, as well as mouse DX5(+) NK cells. The hepatocyte-derived chemotactic activity for mouse T cells but not NK cells was ablated by Abs specific for Mig and Crg-2. These results suggest that parenchymal cells in some organs may contribute substantially to initiation and/or amplification of inflammatory or antitumor responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238618     DOI: 10.4049/jimmunol.166.6.3763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Regulation of hepatocyte fate by interferon-γ.

Authors:  Christopher J Horras; Cheri L Lamb; Kristen A Mitchell
Journal:  Cytokine Growth Factor Rev       Date:  2011-02-18       Impact factor: 7.638

Review 3.  CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus.

Authors:  Zahra Ahmadi; Mohammad Kazemi Arababadi; Gholamhossin Hassanshahi
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

4.  IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.

Authors:  K L Knutson; M L Disis
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

5.  Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.

Authors:  K Kakimi; T E Lane; S Wieland; V C Asensio; I L Campbell; F V Chisari; L G Guidotti
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

Review 6.  Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan
Journal:  Clin Dev Immunol       Date:  2013-12-08

Review 7.  Analysis of potential biomarkers of response to IL-12 therapy.

Authors:  Emily Schwarz; William E Carson
Journal:  J Leukoc Biol       Date:  2022-07-04       Impact factor: 6.011

8.  The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.

Authors:  Toshihisa Semba; Motoi Nishimura; Satomi Nishimura; Osamu Ohara; Takayuki Ishige; Sayaka Ohno; Ken Nonaka; Kazuyuki Sogawa; Mamoru Satoh; Setsu Sawai; Kazuyuki Matsushita; Fumio Imazeki; Osamu Yokosuka; Fumio Nomura
Journal:  BMC Gastroenterol       Date:  2013-07-23       Impact factor: 3.067

9.  Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients.

Authors:  Hamid Najmaddini; Gholamhossein Hassanshahi; Hamid Ostadebrahimi; Hoda Barkhordari; Habibeh Mashayekhi; Mina Nazari; Mozhgan Moogooei; Yassin Safari Arababadi; Fatemeh Peighambari; Mojgan Noroozi Karimabad
Journal:  Ann Saudi Med       Date:  2014 Mar-Apr       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.